Selegiline hydrochloride (Anipryl) in dogs with cognitive dysfunction syndrome: noncomparative open-label study
In a single-arm open-label study, 641 dogs with clinical signs of canine cognitive dysfunction syndrome received oral selegiline hydrochloride at 0.5 to 1.0 mg/kg once daily for 60 days. Responses at days 30 and 60 were similar; on day 60, 77.2% of dogs showed overall improvement, with sign-specific response rates from 67.8% to 77.8%. Diarrhea (4.2%), anorexia (3.6%) and vomiting/salivation (3.4%) were the most frequent adverse events.
Record
| Design | single-arm trial |
|---|---|
| Status | completed |
| Intervention | Selegiline hydrochloride (Anipryl), oral |
| Intervention class | drug |
| Comparator | None (noncomparative open-label study) |
| Dose regimen | 0.5 to 1.0 mg/kg orally once daily |
| Duration | 60 days |
| Dogs | 641 |
| Population note | 641 dogs treated |
| Other | Clinical signs consistent with canine cognitive dysfunction syndrome (CDS) |
| Primary outcome | Overall improvement and response by clinical sign on days 30 and 60; adverse events |
| Result (as reported) | Response to selegiline treatment on days 30 and 60 were similar. On day 60, 77.2% of dogs showed an overall improvement; response to treatment by clinical sign ranged from 67.8% (activity or sleep/wake cycle) to 77.8% (disorientation and interaction with family members). Diarrhea (4.2%), anorexia (3.6%), and vomiting/salivation (3.4%) were noted most frequently. Results of this study indicate the majority of the dogs with CDS responded to treatment with Anipryl by day 30. |
| Tags | cognition, drug, selegiline, cognitive-dysfunction, open-label |
Notes: Kind follows the title wording (noncomparative open-label study). The title places the study in a clinical setting, but the abstract does not state whether dogs were client-owned; sponsor not stated.
Sources and verbatim quotes
A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting. (2001) PMID 19753696 (results)
Six hundred forty-one dogs with clinical signs consistent with canine cognitive dysfunction syndrome (CDS) were treated orally with selegiline hydrochloride at 0.5 to 1.0 mg/kg once daily for 60 days.
Response to selegiline treatment on days 30 and 60 were similar. On day 60, 77.2% of dogs showed an overall improvement; response to treatment by clinical sign ranged from 67.8% (activity or sleep/wake cycle) to 77.8% (disorientation and interaction with family members).
All dogs enrolled in the study were monitored for possible adverse events; diarrhea (4.2%), anorexia (3.6%), and vomiting/salivation (3.4%) were noted most frequently.
Results of this study indicate the majority of the dogs with CDS responded to treatment with Anipryl by day 30.
Reproduce: canine_trial_search(trial_id="selegiline-cds-open-label-2001") in dog-geroscience-mcp; dataset canine-trial-registry.